anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Adults 

PEPCID inhibited both basal and nocturnal gastric secretion, as well as secretion stimulated by food and pentagastrin. After oral administration of PEPCID, the onset of the antisecretory effect occurred within one hour; the maximum effect was dose-dependent, occurring within one to three hours. Duration of inhibition of secretion by doses of 20 mg and 40 mg was 10 to 12 hours. 

Single evening oral doses of 20 mg and 40 mg inhibited basal and nocturnal acid secretion in all subjects; mean nocturnal gastric acid secretion was inhibited by 86% and 94%, respectively, for a period of at least 10 hours. The same doses given in the morning suppressed food-stimulated acid secretion in all subjects. The mean suppression was 76% and 84%, respectively, 3 to 5 hours after administration, and 25% and 30%, respectively, 8 to 10 hours after administration. In some subjects who received the 20 mg dose, however, the antisecretory effect was dissipated within 6 to 8 hours. There was no cumulative effect with repeated doses. The nocturnal intragastric pH was raised by evening doses of 20 mg and 40 mg of PEPCID to mean values of 5.0 and 6.4, respectively. When PEPCID was given after breakfast, the basal daytime interdigestive pH at 3 and 8 hours after 20 mg or 40 mg of PEPCID was raised to about 5. 

PEPCID had little or no effect on fasting or postprandial serum gastrin levels. Gastric emptying and exocrine pancreatic function were not affected by PEPCID. 

In clinical pharmacology studies, systemic effects of PEPCID in the CNS, cardiovascular, respiratory or endocrine systems were not noted. Also, no anti-androgenic effects were noted. Serum hormone levels, including prolactin, cortisol, thyroxine (T4), and testosterone, were not altered after treatment with PEPCID. 

Pediatric Patients 

Pharmacodynamics of famotidine, assessed by gastric pH, were evaluated in 5 pediatric patients 2 to 13 years of age using the sigmoid Emax model. These data suggest that the relationship between serum concentration of famotidine and gastric acid suppression is similar to that observed in adults (see Table 3).

In a study examining the effect of famotidine on gastric pH and duration of acid suppression in pediatric patients, four pediatric patients ages 11 to 15 years of age using the oral formulation at a dose of 0.5 mg/kg, maintained a gastric pH above 5 for 13.5 ± 1.8 hours.
A medical implant verification card (MIVC) having information provided on one or both sides thereof. Information for enabling access to a Medical Implant Verification Account (MIVA) of a patient is one the card. An image showing a medical implant as implanted within a body of the patient (e.g., reproduction of an x-ray image) is on the card. An image of an actual implant operation scar of the patient is on the card. The implant operation scar image shows a scar on the body of the patient resulting from implantation of the medical implant within the body of the patient. Implant identification information designating a type of the medical implant is on the card. Information designating a name of a surgeon having performed the operation for implanting the medical implant and/or information for contacting the surgeon is on the card.
Venlafaxine hydrochloride extended-release capsules USP for once-a-day oral administration contains venlafaxine hydrochloride USP, a serotonin and norepinephrine reuptake inhibitor (SNRI).

Venlafaxine is designated (R/S)-1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl] cyclohexanol hydrochloride or (±)-1-[α- [(dimethylamino)methyl]-p-methoxybenzyl] cyclohexanol hydrochloride and has the empirical formula of C17H27NO2 HCl. Its molecular weight is 313.87. The structural formula is shown as follows.

Venlafaxine hydrochloride USP is an off-white to white crystalline powder, soluble in methanol.

Venlafaxine hydrochloride extended-release capsules USP are formulated as extended-release capsule for once-a-day oral administration. Drug release is controlled by diffusion through the coating membrane on the mini-tablets and is not pH dependent. Capsules contain venlafaxine hydrochloride USP equivalent to 37.5 mg, 75 mg, or 150 mg venlafaxine. Inactive ingredients consist of basic butylated methacrylate copolymer, ethyl cellulose, gelatin, medium chain triglycerides, microcrystalline cellulose, povidone, red iron oxide, sodium stearyl fumarate, talc and titanium dioxide. In addition to the above 37.5 mg consists of black iron oxide and yellow iron oxide. 

The components of the black imprinting ink used in the venlafaxine hydrochloride extended-release capsules USP, 37.5 mg and 75 mg are black iron oxide, potassium hydroxide, propylene glycol, shellac and strong ammonia solution The components of the white imprinting ink used in the venlafaxine hydrochloride extended-release capsules USP, 150 mg are ammonium hydroxide, propylene glycol, simethicone, shellac and titanium dioxide.
The invention belongs to the field of biology and medicine, and relates to a novel alpha-conotoxin peptide TxIE, a pharmaceutical composition and application thereof. Specifically, the invention relates to an isolated polypeptide which is a polypeptide with an amino acid sequence shown as SEQ ID NO. 1 or a mutant thereof; wherein the amino acid sequence of the mutant is that glycine at the 1 st position in the sequence shown in SEQ ID NO. 1 is replaced by glutamic acid or aspartic acid; and/or the methionine at position 15 in the sequence shown in SEQ ID NO. 1 is replaced by alanine, leucine or isoleucine. The polypeptide provided by the invention can specifically block acetylcholine receptors, has high selectivity and strong blocking activity particularly on drug targets alpha 6/alpha 3 beta 2 beta 3 nAChR of addiction and parkinsonism and drug targets alpha 6/alpha 3 beta 4 nAChR related to pain, and has the potential of preparing drugs for stopping smoking, stopping drug or easing pain or preparing drugs for preventing and/or treating parkinsonism, depression, dementia and schizophrenia.
Group II: The study group. Participants in this group received NDT based upper extremity rehabilitation + Cogniboard® Light Trainer training. Number of the participants were 19.
The investigators recently published data showing systolic blood pressure is attenuated during cycling exercise in males but not females following acute partial sleep deprivation, compared to a night of normal sleep, despite no differences in power output. The mechanisms responsible for this sex difference remain unknown. The investigators have pilot data that suggests males have a reduction in cardiac output following acute partial sleep deprivation, but females do not. Therefore, the primary purpose of this study is to assess hemodynamics (blood pressure, stroke volume, and cardiac output) and plasma volume during cycling exercise following a night of normal sleep and partial sleep deprivation in otherwise healthy males and females.

Thirty young healthy adults (50% female) will be recruited to undergo three visits. The first visit will assess maximal oxygen uptake to determine aerobic fitness and metabolic exercise intensity zones. The following two testing visits will be randomized and will be completed after a night of normal sleep or acute partial sleep deprivation (early awakening, 40% normal sleep duration). Sleep will be measured 1-week before each visit subjectively (questionnaire) to determine habitual sleep timing and duration and objectively (wrist actigraphy) the night before each testing visit. Each testing visit will require participants to complete a constant load 60-minute bout of cycling. Before, during, and after the exercise protocol, the investigators will measure hemodynamics and plasma volume. Venous blood samples will be collected via intravenous lines.
The objective is to evaluate the effect of administration of resveratrol on GV in individuals with T2DM inadequately controlled on metformin, for which we will conduct a double-blind trial, randomized, placebo control group, each group 11 male and female patients 30-60 years of age with T2DM inadequately controlled with metformin \[2000 mg / day and glycosylated hemoglobin A1c (A1C) ≥% 7\], with body mass index \[BMI\] form 25.0 to 34.9 kg / m2. Randomization will determine who will receive the intervention during the 8-week trial \[resveratrol capsules, 500 mg 3 times daily with the first bite of each meal or approved placebo capsules\], both groups also continue with metformin. The clinical findings and laboratory tests include a metabolic profile and biosafety, which will be made at baseline and at 8 weeks. Body weight, body fat, BMI and blood pressure will be determined during the initial and final visit, likewise, plasma glucose concentrations every hour recorded over 72 hours by continuous monitoring system outpatient glucose \[MACG\] via iPro ™ 2 \[Medtronic MiniMed, Northridge\] system, through which the mean amplitude of glucose excursions \[MAGE\] is calculated and AUC glucose, which will serve to assess the GV. Adverse events and adherence to treatment will be documented. Statistical analysis: Mann-Whitney U test, Wilcoxon and Fisher exact test. It is considered with significance at p \<0.05.
A new method for producing precipitated silicas having a unique combination of physical and chemical properties is disclosed. The silicas are produced by acidulating a solution of an alkali metal silicate having a specific SiO2/Na2O mol ratio with an acid until precipitation just begins. At this point, the reaction mass is aged for a period of time and thereafter the acid addition is continued until the precipitated product is obtained. Products produced in accordance with the invention exhibit lower wet cake moisture and are characterized by their low structure, low oil absorption, high abrasiveness and high pack density, and as such are distinctly different from silicas used as reinforcing fillers in rubber. In a particularly advantageous embodiment, an adduct material, such as aluminum, is added to control the refractive index of the precipitated pigment silica. Products produced in this manner have particular utility for use as abrasion and gelling agents in clear toothpaste compositions.
INTRODUCTION: The management of Factor XI deficiency is challenged by a variable association between FXI level and bleeding phenotype. Additionally, there is scarce data describing management strategies and their outcomes, specifically bleeding, thrombosis, and other complications.
AIMS: To evaluate bleeding, thrombosis, and other complications in individuals with severe FXI deficiency seen in our comprehensive haemophilia treatment centre (HTC). Peri-procedural management strategies and the resulting impact on bleeding and other clinically relevant outcomes were reported.
METHODS: Retrospective review of the electronic medical record of adult patients with severe FXI deficiency (< 20% activity) seen at a New York City comprehensive HTC between 2017 and 2022. Procedures, haemostatic management, and outcomes were collected and analysed.
RESULTS: We identified 38 individuals (64%) females with severe FXI deficiency. The mean age was 56 ± 21 years (SD). The median FXI activity level was 3% (IQR: 1-8%). The mean BAT score was 3.1 ± 2.4; (52%) individuals did not have a history of bleeding. A total of 256 surgeries and procedures were performed. There was reduced bleeding with preventative or reactive treatment during procedures. Arterial but not venous thrombotic complications were observed. Plasma was mostly used for procedures associated with higher risk of bleeding and antifibrinolytics for procedures at sites of high fibrinolysis.
CONCLUSIONS: Current management strategies pose a burden of care for these patients and manifested as nonbleeding adverse events and changes in clinical management. These findings highlight the need for novel investigation in predicting and managing bleeding for individuals with severe FXI deficiency.
Respiratory mechanics and regional ventilation will be monitored by electrical impedance tomography (Enlight 1800 and 2100, Timpel). Esophageal and gastric pressures will be obtained by placing an esophageal/gastric balloon cathether (Nutrivent ®), validation concerning position will be done through modified Baydur maneuver (delta esophageal/delta airway pressure = 0.8-1.2). The hardware Pneumodrive will be used to inflate the balloon and store the airway, gastric and esophageal pressures.

Initially the patients will be monitored with EIT for aproximately 30 minutes after pletismography stabilization. Then, an arterial blood-gas sample shall be collected for analysis. Next, three expiratory and three inspiratory pauses of at least two seconds will be realized with intervals of eight respiratory cycles between them, allowing plateau pressure to be recorded and global and regional driving pressure to be estimated. All this data will be stored for later analysis. The same procedures and measurements shall be made sequentially with a 50% higher pressure support and with a 50% lower pressure support.
Patients will receive one weekly session for 5 weeks including best-evidence manual therapy and an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles. The exercise program will be asked to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
PROBLEM TO BE SOLVED: To obtain the subject enhancer introducing abnormal cells having increased cell number by acquiring abnormal proliferation potency to apoptosis and safe to a human body by including hyaluronic acid as an active component. SOLUTION: This enhancer contains hyaluronic acid (a linear polymeric polysaccharide obtained by β1→3 bonding of β-D-N-acetylglucosamine with β-D-glucuronic acid) preferably having 1,000-60,000 Da weight-average molecular weight or its salt, preferably a sodium salt as an active component. The enhancer effectively induces apoptosis by irritating abnormal cell (e.g. cancer cell, synovial cell of an animal of chronic rheumatic synovitis, etc.), strongly manifesting cell membrane antigen CD44 with hyaluronic acid. Preferably, the enhancer is used as a liquid formulation such as injection agent in using as a medical agent.
PCT No. PCT/FR90/00831 Sec. 371 Date May 13, 1992 Sec. 102(e) Date May 13, 1992 PCT Filed Nov. 20, 1990 PCT Pub. No. WO91/07142 PCT Pub. Date May 30, 1991.A crown-root reconstitution system and method of manufacturing a physiological dental securing peg in which a crown reconstituting material (3) is placed between a peg (1) and sound dentine walls (2a). The peg is formed of a composite material and includes high strength fibers (5) embedded parallel to one another, elongated in its axial direction, continuous from one end to the other end thereof. An epoxy resin matrix is formed, and a transverse modulus of elasticity of the order of magnitude of the average of that of the dentine in the amount of 18 GPa and a longitudinal compression-tensile strength and shear strength greater than corresponding average values for the dentine is provided by tensioning all of the fibers equally and pre-stressing all of the fibers in traction. The peg is manufactured by extruding the resin around a wick of continuous fibers which are all equally tensioned and pre-stressed in traction, allowing the resin to harden, cutting the ring of composite material after the resin is hardened, and machining the peg by slicing so as to obtain two coaxial cylindro-conical parts of different diameters, in line with each other, each comprising a cylindrical shank (6, 8) followed by a respective truncated part of a frustrum of a cone (7, 9) converging towards the apex of the peg.
Risk Summary

  


Contraceptive hormones and/or metabolites are present in human milk. COCs can reduce milk production in breast-feeding females. This reduction can occur at any time but is less likely to occur once breast-feeding is well-established. When possible, advise the nursing female to use other methods of contraception until she discontinues breast-feeding. (see DOSAGE AND ADMINISTRATION). The developmental and health benefits of breast-feeding should be considered along with the mother’s clinical need for Chateal EQ and any potential adverse effects on the breast-fed child from Chateal EQ or from the underlying maternal condition.
Participants will have contact with a menopause counselor 6 times over 8 weeks. The first session will be in-person at a private research office. All other contacts will be by telephone. Women who are unable to attend the in-person session will receive a phone call. All in-person and telephone consultations are designed to last 20-30 minutes. Participants will receive information about menopausal changes and ways to develop symptom management strategies. Women in the MEC will keep a daily sleep diary. The day before each telephone session, the participant will email that week's completed diary to a secure email address accessible only by the counselor; women who are unable to use email will provide their data by telephone directly to the counselor. During the weekly telephone calls, the reading material will be discussed and the sleep diary will be reviewed.
As with all therapeutic oligonucleotides, there is a potential for immunogenicity. 

Immunogenicity assay results are highly dependent on the sensitivity and specificity of the assay and may be influenced by several factors such as: assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to tofersen with the incidence of antibodies to other products may be misleading. 

The immunogenic response to QALSODY was evaluated in 166 patients with post-baseline plasma samples for anti-drug antibodies (ADAs). Overall, 97 QALSODY-treated patients (58.4%) developed treatment-emergent ADAs, of which 14 were transient and 83 were persistent. The presence of anti-drug antibodies (ADA) appeared to decrease plasma tofersen clearance by 32%. Effects of ADA on CSF tofersen clearance is unknown. No discernible effects of ADAs on total SOD1 protein reduction or plasma NfL reduction have been observed. No discernible effects of ADAs on safety (incidence of AEs including hypersensitivity, anaphylactic reaction, and angioedema) have been observed. Medical review of individual cases of serious neurological events also showed no association with ADA status.
OBJECTIVE: Diet-derived circulating antioxidants have been associated with functional outcome after ischemic stroke (IS), but the causality remains unclear. The aim of our study is to explore the potential causal effect of diet-derived circulating antioxidants on long-term functional outcome (at 3 months) following IS through the utilization of the Mendelian randomization (MR) approach.
MATERIALS AND METHODS: For this two-sample MR analysis, genetic variants associated with the diet-derived circulating antioxidants, including selenium, zinc, vitamin A (retinol), vitamin C, and vitamin E (α-tocopherol and γ-tocopherol), were identified in a large-scale Genome-Wide Association Studies (GWAS) database and utilized as instrumental variables (IVs). Summary data for long-term functional outcome after IS were obtained from the Genetics of Ischemic Stroke Functional Outcome (GISCOME) network of 6021 patients. Our study used the Inverse-variance weighting method as our primary MR method and also performed a series of sensitivity analyses for pleiotropy and heterogeneity.
RESULTS: We observed that selenium (odds ratio (OR)=0.81; 95 % confidence interval (CI): 0.68-0.97; p=0.02) was significantly associated with poor functional outcome (modified Rankin Scale score≥3) after IS. Genetic liabilities to other diet-derived circulating antioxidants were not strongly associated with functional outcome after IS (all p>0.05). Sensitivity analyses confirmed the reliability of these results.
CONCLUSION: This MR study suggested the positive effect of selenium on the long-term functional outcome after IS. Giving a longer period of selenium exposure can be used as a potential treatment to improve recovery after IS.
Injectable platelet rich fibrin: 10-mL sample of whole venous blood will be drawn from the patient's forearm and transferred into two plain plastic test tubes without an anticoagulant and will centrifuge immediately at 700 rpm for 3 minutes (60×g) . After centrifugation, the upper yellow fluid liquid (i-PRF) will be collected as close as possible to the layer of red cells the will be mixed with 250 micromole of Vitamin C.
The present invention relates to large capacity compound red sage root injection and a preparation method thereof. Red sage root fine liquor, dalbergia wood fine liquor, dextrose or sodium chloride, and water for injection are prepared into the red sage root injection. The injection of 250 ml contains the following effective components of crude drugs: 8 to 320 grams of red sage roots, and 4 to 80 grams of dalbergia wood. The preparation method comprises the following steps: tanshinol sinking liquor is added with water, the tanshinol sinking liquor and the water are uniformly stirred, refrigerated, positioned without movement, filtered, decolored and concentrated, and the red sage root fine liquor is obtained; the dalbergia wood fine liquor is prepared in a distillation method; concentration and dilution are carried out, and a finished product-the large capacity compound red sage root injection is obtained. Compared with the prior art, the present invention provides the large capacity compound red sage root injection, the therapeutic effect of the large capacity compound red sage root injection is obviously better than the existing compound red sage root injection, and the large capacity compound red sage root injection has the characteristics of easy preparation, large capacity and good therapeutic effect. The large capacity compound red sage root injection can be used for clinical intravenous drip infusion.
PURPOSE:To obtain the title cells rich in saponins having hepatopathy-mitigating and anti-allergic effects by making a culture, at a constant cell density based on the culture solution, of callus cells induced from the tissue pieces of a Bupleurum sp. plant. CONSTITUTION:The leaves and stems of a Bupleurum sp. plant (e.g. Bupleurum falcatnm) are washed, sterilized and cut aseptically into pieces; which are then put to culture in the dark at 25 deg.C, and callus cells are obtained after 4 weeks. Thence, the callus cells are put to shaking culture in the dark at 25 deg.C for 6 weeks under a constant cell density within the range from 1.0 to 40.0g/l based on the culture solution, thus obtaining the objective callus cells rich in useful components, e.g. saponins such as SAIKO saponin D.
Participants (n=10) will be enrolled and assigned chronologically to one of five excision time points: Weeks 2 (n=10), 4 (n=2), 6 (n=2), 8 (n=2), and 12 (n=2) post-injection. Implants will be injected on Day 0. All participants will be administered up to five (5) 2 milliliter (mL) subcutaneous injections of acellular adipose tissue (AAT) via sterile injection into the area identified for planned excision. Total injected AAT volume per patient will not exceed 10 mL.